Clinical Trial Update: Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake [Phase 3]

View source ↗

Summary

Phase 3 safety trial of OPC-61815 Injection in patients with congestive heart failure who cannot take oral medication has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• OPC-61815 Injection

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Congestive Heart Failure | Phase 3 | Status: COMPLETED | Results posted: 2021-09-05